Cost-effectiveness analysis of the use of PNEU-C-21 in adults aged ≥50 years in Canada
Background This study analyzed the health and economic outcomes of the 21-valent pneumococcal conjugate vaccine (PNEU-C-21; CAPVAXIVE®) compared to either PNEU-C-20 or PNEU-P-23. Cohorts in the cost-effectiveness analyses included vaccine-naïve 57- and 65-year-olds and vaccine-experienced 70-year-ol...
Kaydedildi:
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Taylor & Francis Group
2026-12-01
|
| Seri Bilgileri: | Expert Review of Vaccines |
| Konular: | |
| Online Erişim: | https://www.tandfonline.com/doi/10.1080/14760584.2025.2608811 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|